<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144399</url>
  </required_header>
  <id_info>
    <org_study_id>H-18028566</org_study_id>
    <nct_id>NCT05144399</nct_id>
  </id_info>
  <brief_title>Accelerated Treatment of Endocarditis</brief_title>
  <acronym>POET II</acronym>
  <official_title>Accelerated Treatment of Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Existing guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks&#xD;
      one or more types of intravenously administered antibiotics. The long hospitalization&#xD;
      increases several risks for the patient, including mental strain and increased loss of&#xD;
      function. Furthermore, it poses a significant financial burden on the health systems. Current&#xD;
      guidelines fail to use available clinical and paraclinical, data collected from patients&#xD;
      (echo, temperature, CRP, leukocytes, procalcitonin etc.) to determine duration of treatment.&#xD;
      A strategy including these data in treatment algorithms ensures an individualized treatment,&#xD;
      targeting the individual patient's course and response to treatment. Thus, the purpose of&#xD;
      this open-label, prospective, non-inferiority, RCT study is to investigate the safety and&#xD;
      effectiveness of shortening treatment of endocarditis based on the individual patient's&#xD;
      initial treatment response, sampling 750 patients, approx. 200 patients with each type of&#xD;
      bacteria (Streptococci; Enterococcus faecalis; Staphylococcus aureus).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint of: All cause mortality, Bacteremia with primary pathogen, embolic episodes, not planned Heart surgery</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>The primary endpoint is a combined endpoint consisting of the following events occurring within six months after the earliest time of potential treatment discontinuation: Death; Embolisms; Bacteraemia with the same microorganism; Heart surgery not planned at the time of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expenses associated with admission and treatment</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Combined endpoint consisting of expenses due to i admission ii medication iii transportation iv surgery v imaging vi home care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of admission</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Duration of admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic treatment</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Duration of antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of catheter complication</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Frequency of catheter complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned Heart surgery</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>• Unplanned cardiac valve surgery defined as any cardiac surgery which is not planned at the time of randomization. Data will be extracted from the electronic patient journal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embolic events</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Embolic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-bacteremia with the primary pathogen</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>• Relapse of bacteremia defined as a positive blood culture with the same microorganism as during the initial IE admission (streptococci spp., S. aureus, or E. faecalis). Data will be extracted from the electronic patient journal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Accelerated antibiotic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated shorter than usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard length of antibiotic treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are receiving the standard length of antibiotic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Accelerated antibiotic treatment</intervention_name>
    <description>E. faecalis uncomplicated: 4 weeks.&#xD;
E. faecalis complicated: 4 weeks.&#xD;
S. aureus uncomplicated: 2 weeks.&#xD;
S. aureus complicated: 4 weeks.&#xD;
Streptococci spp. NVE: 2 weeks.&#xD;
Streptococci spp. PVE or abscess: 3 weeks.&#xD;
Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.&#xD;
Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.&#xD;
Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.&#xD;
NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.</description>
    <arm_group_label>Accelerated antibiotic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment length</intervention_name>
    <description>E. faecalis uncomplicated: 6 weeks.&#xD;
E. faecalis complicated: 6 weeks.&#xD;
S. aureus uncomplicated: 4 weeks.&#xD;
S. aureus complicated: 6 weeks.&#xD;
Streptococci spp. NVE: 4 weeks.&#xD;
Streptococci spp. PVE or abscess: 6 weeks.&#xD;
Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.&#xD;
Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.&#xD;
Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.&#xD;
NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.</description>
    <arm_group_label>Standard length of antibiotic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted with infectious endocarditis (duke criteria) &lt; 14 days of relevant antibiotic&#xD;
             treatment for endocarditis One of the following bacteria: Streptococci, enterococcus&#xD;
             faecalis, staphylococcus aureus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known immune incompetency, Relapse endocarditis with 6 months, Unable to give informed&#xD;
             concent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshositalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Bundgaard</last_name>
      <phone>+4535450512</phone>
      <email>henning.bundgaard@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kasper iversen</last_name>
      <phone>+4538686009</phone>
      <email>kasper.karmark.iversen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Kasper Iversen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

